regenerative fibroblasts from umbilical-cord tissue. Cell-free exosomes and iPSC-derived products are the fastest-growing area in 2026 — easier to manufacture and store, with 200+ active trials — though most uses remain investigational.
For most conditions, therapy using Fibroblasts from Wharton's Jelly is investigational — not an approved cure — outside established blood/immune transplantation. Check the published evidence and whether a registered trial is open with our candidacy check and cell-type selector.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational information only. Fibroblasts from Wharton's Jelly protocols for most conditions remain investigational; outcomes vary by patient. Not medical advice.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية